Drug Enforcement Administration December 2022 – Federal Register Recent Federal Regulation Documents

Bulk Manufacturer of Controlled Substances Application: Isosciences, LLC
Document Number: 2022-28205
Type: Notice
Date: 2022-12-28
Agency: Drug Enforcement Administration, Department of Justice
Isosciences, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Schedules of Controlled Substances: Removal of Fenfluramine From Control
Document Number: 2022-27400
Type: Rule
Date: 2022-12-23
Agency: Drug Enforcement Administration, Department of Justice
With the issuance of this final rule, the Drug Enforcement Administration removes fenfluramine (chemical name: N-ethyl-[alpha]- methyl-3-(trifluoromethyl)phenethylamine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts is possible, from the schedules of the Controlled Substances Act. Prior to the effective date of this rule, fenfluramine was a schedule IV controlled substance. This action removes the regulatory controls and administrative, civil, and criminal sanctions applicable to controlled substances, including those specific to schedule IV controlled substances, on persons who handle (manufacture, distribute, reverse distribute, dispense, engage in research, import, export, conduct instructional activities or chemical analysis with, or possess) or propose to handle fenfluramine.
Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
Document Number: 2022-27278
Type: Proposed Rule
Date: 2022-12-23
Agency: Drug Enforcement Administration, Department of Justice
The Administrator of the Drug Enforcement Administration is providing this notice of intent to publish a temporary order to schedule five synthetic benzodiazepine substances, as identified in this notice, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specified controlled substances.
Jennings Staley, M.D.; Decision and Order
Document Number: 2022-27480
Type: Notice
Date: 2022-12-20
Agency: Drug Enforcement Administration, Department of Justice
Allan Alexander Rashford, M.D.; Decision and Order
Document Number: 2022-27479
Type: Notice
Date: 2022-12-19
Agency: Drug Enforcement Administration, Department of Justice
Bulk Manufacturer of Controlled Substances Application: Stepan Company; Correction
Document Number: 2022-26928
Type: Notice
Date: 2022-12-15
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) published a document in the Federal Register on August 9, 2022, concerning an application for an Importer of Controlled Substances. The document contained an incorrect drug schedule for coca leaves.
Importer of Controlled Substances Application: VHG Labs dba LGC Standards
Document Number: 2022-26925
Type: Notice
Date: 2022-12-12
Agency: Drug Enforcement Administration, Department of Justice
VHG Labs dba LGC Standards has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Document Number: 2022-26922
Type: Notice
Date: 2022-12-12
Agency: Drug Enforcement Administration, Department of Justice
Scottsdale Research Institute has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Importer of Controlled Substances Application: Lyndra Therapeutics
Document Number: 2022-26920
Type: Notice
Date: 2022-12-12
Agency: Drug Enforcement Administration, Department of Justice
Lyndra Therapeutics has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA, LLC
Document Number: 2022-26913
Type: Notice
Date: 2022-12-12
Agency: Drug Enforcement Administration, Department of Justice
Sterling Pharma USA, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Schedules of Controlled Substances: Placement of Methiopropamine in Schedule I
Document Number: 2022-26805
Type: Rule
Date: 2022-12-09
Agency: Drug Enforcement Administration, Department of Justice
With the issuance of this final rule, the Drug Enforcement Administration places N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine), including its salts, isomers, and salts of isomers in schedule I of the Controlled Substances Act. This action is being taken to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle methiopropamine.
Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Alm Management
Document Number: 2022-26208
Type: Notice
Date: 2022-12-02
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.
Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Attitude Wellness
Document Number: 2022-26207
Type: Notice
Date: 2022-12-02
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.
Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023
Document Number: 2022-26351
Type: Notice
Date: 2022-12-02
Agency: Drug Enforcement Administration, Department of Justice
This final order establishes the initial 2023 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Kerry Farms LLC
Document Number: 2022-26178
Type: Notice
Date: 2022-12-01
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.